Progyny (NASDAQ:PGNY) Now Covered by Analysts at Wells Fargo & Company

Stock analysts at Wells Fargo & Company started coverage on shares of Progyny (NASDAQ:PGNY) in a report issued on Wednesday, Benzinga reports. The brokerage set an “overweight” rating and a $37.00 price target on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 48.70% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a report on Tuesday, September 8th. JPMorgan Chase & Co. raised their price objective on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. Canaccord Genuity Group set a $35.00 target price on Progyny in a research report on Friday, August 7th. Citizens Jmp lifted their price objective on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Finally, BTIG Research boosted their price objective on shares of Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.36.

Progyny Stock Performance

PGNY opened at $24.88 on Wednesday. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 1.76 and a beta of 0.99. The company has a fifty day moving average of $27.49 and a 200 day moving average of $24.69. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $33.06.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%.The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. During the same period in the prior year, the company earned $0.19 earnings per share. The firm’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts forecast that Progyny will post 1.25 earnings per share for the current year.

Insider Transactions at Progyny

In related news, Director Kevin Gordon sold 11,500 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the sale, the director owned 6,792 shares of the company’s stock, valued at approximately $189,768.48. This represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Allison Swartz sold 3,903 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the sale, the executive vice president owned 75,816 shares of the company’s stock, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

Several hedge funds have recently made changes to their positions in PGNY. Hsbc Holdings PLC acquired a new position in shares of Progyny during the second quarter worth approximately $760,000. AWM Investment Company Inc. bought a new position in Progyny in the 2nd quarter worth approximately $6,343,000. Bank of America Corp DE lifted its holdings in Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after buying an additional 511,609 shares in the last quarter. Royal Bank of Canada boosted its position in Progyny by 98.0% in the 1st quarter. Royal Bank of Canada now owns 218,434 shares of the company’s stock valued at $3,709,000 after buying an additional 108,137 shares during the last quarter. Finally, CenterBook Partners LP increased its stake in shares of Progyny by 36.2% in the 4th quarter. CenterBook Partners LP now owns 578,171 shares of the company’s stock valued at $14,847,000 after buying an additional 153,778 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.